All In Biotech

Drug Trial Radar · NCT02321202

Omega-3 Fatty Acid-Based Parenteral Nutrition Improves Postoperative Recovery for Cirrhotic Patients With Liver Cancer

Last checked: Nov 20, 2026Latest source record: Aug 22, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 320 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

320

Actual

Start

Mar 2010

Primary completion

Sep 2013

Study completion Nov 2013

Sponsor

Lead sponsor
Huazhong University of Science and TechnologyAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Dec 22, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, outcomes assessor)
Primary purpose
Prevention
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The safety and efficacy of ω-3 fatty acid in patients with liver cancer followed hepatectomy is not known. This study provided evidences that ω-3 fatty acid-based parenteral nutrition improved postoperative recovery for cirrhotic patients with liver cancer underwent hepatectomy..

Conditions

  • Liver Cancer
  • Cirrhosis

Interventions

  • Omega-3 Fatty Acid-Based Parenteral NutritionDrug

    Glucose, lipid emulsion, amino acids, fat-and water-soluble vitamins as well as electrolytes were compounded in an "All-In-One" manner. 20% Structolipid and 10% Omegaven (ω-3 fatty acid \[FA\] mainly; Fresenius-Kabi, Germany) were applied to the trial group, but only Structolipid (ω-6 FA mainly) to the control group for 5 consecutive days postoperatively.

  • StructolipidDrug

    Glucose, lipid emulsion, amino acids, fat-and water-soluble vitamins as well as electrolytes were compounded in an "All-In-One" manner. 20% Structolipid and 10% Omegaven (ω-3 FA mainly; Fresenius-Kabi, Germany) were applied to the trial group, but only Structolipid (ω-6 FA mainly) to the control group for 5 consecutive days postoperatively.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. complications (blood test for liver and renal function, urine output, postoperative complications)Time frame: 14 days postoperatively
  2. hospital stay (time of hospital stay after surgery)Time frame: 14 days postoperatively

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Hepatic Surgery Center of Tongji Hospital

    Wuhan, Hubei, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.